Floatz logo

Autologous Anti-Cd19 Car-Expressing T Lymphocytes

Recurrent Glioblastoma

City of Hope Medical CenterCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

353 Active assets in the Recurrent Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Autologous Anti-Cd19 Car-Expressing T Lymphocytes is also rated in:

cutaneous melanomaDormant
CC
Indicative ·
43 / 100
View asset →
paragangliomaDormant
CC
Indicative ·
43 / 100
View asset →
pheochromocytomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →